drugset / Trial / NCT02253849
Effects of TPV/r on the Pharmacokinetics of Carbamazepine in Healthy Adult Volunteers
NaSingle-groupOpen-labelTreatment
Summary
Study to assess the steady-state pharmacokinetics of carbamazepine (CBZ) at 200 mg or 100 mg twice daily, depending on tolerability, and administered alone and in combination with tipranavir/ritonavir (TPV/r) after a single dose (500/200 mg) and at steady-state (500/200 mg twice-daily)
Timeline
- Start
- 2005-11
- Primary completion
- 2006-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carbamazepine | Small molecule | 100 mg | — |
| Subject | Carbamazepine | Small molecule | 200 mg | — |
| Subject | Ritonavir | Other / unclassified | 200 mg | — |
| Subject | Tipranavir | Small molecule | 500 mg | — |
Indications
No indication recorded.